Boehringer Ingelheim begins trials for ‘Viagra for women’

Share this article:
Boehringer Ingelheim has begun trials on a sex drug that has been dubbed a “Viagra for women,” because it works directly on the pleasure zones of the female brain to restore low libido. The drug, known as flibanserin, was originally tested as an anti-depressant. Participants in those trials reported that while their depression was no better, they had experienced a boost in sexual desire. Boehringer is reportedly conducting four trials on 5,000 women in 220 locations and is hoping to receive approval from the FDA in 2009. Boehringer’s medical director for the UK, Dr. Charles de Wet, told the British newspaper The Times that “no excessive sexual side effects have been reported from the treatment in any clinical trial.” Flibanserin takes several weeks for a significant effect to build up in the brain, meaning that, unlike Viagra, it cannot be “popped” in advance of an evening out.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...